Cargando…

Pharmaceutical quality assurance of local private distributors: a secondary analysis in 13 low-income and middle-income countries

INTRODUCTION: The rapid globalisation of the pharmaceutical production and distribution has not been supported by harmonisation of regulatory systems worldwide. Thus, the supply systems in low-income and middle-income countries (LMICs) remain exposed to the risk of poor-quality medicines. To contrib...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Assche, Kerlijn, Nebot Giralt, Ariadna, Caudron, Jean Michel, Schiavetti, Benedetta, Pouget, Corinne, Tsoumanis, Achilleas, Meessen, Bruno, Ravinetto, Raffaella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001909/
https://www.ncbi.nlm.nih.gov/pubmed/29915671
http://dx.doi.org/10.1136/bmjgh-2018-000771
_version_ 1783332103749894144
author Van Assche, Kerlijn
Nebot Giralt, Ariadna
Caudron, Jean Michel
Schiavetti, Benedetta
Pouget, Corinne
Tsoumanis, Achilleas
Meessen, Bruno
Ravinetto, Raffaella
author_facet Van Assche, Kerlijn
Nebot Giralt, Ariadna
Caudron, Jean Michel
Schiavetti, Benedetta
Pouget, Corinne
Tsoumanis, Achilleas
Meessen, Bruno
Ravinetto, Raffaella
author_sort Van Assche, Kerlijn
collection PubMed
description INTRODUCTION: The rapid globalisation of the pharmaceutical production and distribution has not been supported by harmonisation of regulatory systems worldwide. Thus, the supply systems in low-income and middle-income countries (LMICs) remain exposed to the risk of poor-quality medicines. To contribute to estimating this risk in the private sector in LMICs, we assessed the quality assurance system of a convenient sample of local private pharmaceutical distributors. METHODS: This descriptive study uses secondary data derived from the audits conducted by the QUAMED group at 60 local private pharmaceutical distributors in 13 LMICs. We assessed the distributors’ compliance with good distribution practices (GDP), general quality requirements (GQR) and cold chain management (CCM), based on an evaluation tool inspired by the WHO guidelines ’Model Quality Assurance System (MQAS) for procurement agencies'. Descriptive statistics describe the compliance for the whole sample, for distributors in sub-Saharan Africa (SSA) versus those in non-SSA, and for those in low-income countries (LICs) versus middle-income countries (MICs). RESULTS: Local private pharmaceutical distributors in our sample were non-compliant, very low-compliant or low-compliant for GQR (70%), GDP (60%) and CCM (41%). Only 7/60 showed good to full compliance for at least two criteria. Observed compliance varies by geographical region and by income group: maximum values are higher in non-SSA versus SSA and in MICs versus LICs, while minimum values are the same across different groups. CONCLUSION: The poor compliance with WHO quality standards observed in our sample indicates a concrete risk that patients in LMICs are exposed to poor-quality or degraded medicines. Significant investments are needed to strengthen the regulatory supervision, including on private pharmaceutical distributors. An adapted standardised evaluation tool inspired by the WHO MQAS would be helpful for self-evaluation, audit and inspection purposes.
format Online
Article
Text
id pubmed-6001909
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-60019092018-06-18 Pharmaceutical quality assurance of local private distributors: a secondary analysis in 13 low-income and middle-income countries Van Assche, Kerlijn Nebot Giralt, Ariadna Caudron, Jean Michel Schiavetti, Benedetta Pouget, Corinne Tsoumanis, Achilleas Meessen, Bruno Ravinetto, Raffaella BMJ Glob Health Research INTRODUCTION: The rapid globalisation of the pharmaceutical production and distribution has not been supported by harmonisation of regulatory systems worldwide. Thus, the supply systems in low-income and middle-income countries (LMICs) remain exposed to the risk of poor-quality medicines. To contribute to estimating this risk in the private sector in LMICs, we assessed the quality assurance system of a convenient sample of local private pharmaceutical distributors. METHODS: This descriptive study uses secondary data derived from the audits conducted by the QUAMED group at 60 local private pharmaceutical distributors in 13 LMICs. We assessed the distributors’ compliance with good distribution practices (GDP), general quality requirements (GQR) and cold chain management (CCM), based on an evaluation tool inspired by the WHO guidelines ’Model Quality Assurance System (MQAS) for procurement agencies'. Descriptive statistics describe the compliance for the whole sample, for distributors in sub-Saharan Africa (SSA) versus those in non-SSA, and for those in low-income countries (LICs) versus middle-income countries (MICs). RESULTS: Local private pharmaceutical distributors in our sample were non-compliant, very low-compliant or low-compliant for GQR (70%), GDP (60%) and CCM (41%). Only 7/60 showed good to full compliance for at least two criteria. Observed compliance varies by geographical region and by income group: maximum values are higher in non-SSA versus SSA and in MICs versus LICs, while minimum values are the same across different groups. CONCLUSION: The poor compliance with WHO quality standards observed in our sample indicates a concrete risk that patients in LMICs are exposed to poor-quality or degraded medicines. Significant investments are needed to strengthen the regulatory supervision, including on private pharmaceutical distributors. An adapted standardised evaluation tool inspired by the WHO MQAS would be helpful for self-evaluation, audit and inspection purposes. BMJ Publishing Group 2018-06-09 /pmc/articles/PMC6001909/ /pubmed/29915671 http://dx.doi.org/10.1136/bmjgh-2018-000771 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Research
Van Assche, Kerlijn
Nebot Giralt, Ariadna
Caudron, Jean Michel
Schiavetti, Benedetta
Pouget, Corinne
Tsoumanis, Achilleas
Meessen, Bruno
Ravinetto, Raffaella
Pharmaceutical quality assurance of local private distributors: a secondary analysis in 13 low-income and middle-income countries
title Pharmaceutical quality assurance of local private distributors: a secondary analysis in 13 low-income and middle-income countries
title_full Pharmaceutical quality assurance of local private distributors: a secondary analysis in 13 low-income and middle-income countries
title_fullStr Pharmaceutical quality assurance of local private distributors: a secondary analysis in 13 low-income and middle-income countries
title_full_unstemmed Pharmaceutical quality assurance of local private distributors: a secondary analysis in 13 low-income and middle-income countries
title_short Pharmaceutical quality assurance of local private distributors: a secondary analysis in 13 low-income and middle-income countries
title_sort pharmaceutical quality assurance of local private distributors: a secondary analysis in 13 low-income and middle-income countries
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001909/
https://www.ncbi.nlm.nih.gov/pubmed/29915671
http://dx.doi.org/10.1136/bmjgh-2018-000771
work_keys_str_mv AT vanasschekerlijn pharmaceuticalqualityassuranceoflocalprivatedistributorsasecondaryanalysisin13lowincomeandmiddleincomecountries
AT nebotgiraltariadna pharmaceuticalqualityassuranceoflocalprivatedistributorsasecondaryanalysisin13lowincomeandmiddleincomecountries
AT caudronjeanmichel pharmaceuticalqualityassuranceoflocalprivatedistributorsasecondaryanalysisin13lowincomeandmiddleincomecountries
AT schiavettibenedetta pharmaceuticalqualityassuranceoflocalprivatedistributorsasecondaryanalysisin13lowincomeandmiddleincomecountries
AT pougetcorinne pharmaceuticalqualityassuranceoflocalprivatedistributorsasecondaryanalysisin13lowincomeandmiddleincomecountries
AT tsoumanisachilleas pharmaceuticalqualityassuranceoflocalprivatedistributorsasecondaryanalysisin13lowincomeandmiddleincomecountries
AT meessenbruno pharmaceuticalqualityassuranceoflocalprivatedistributorsasecondaryanalysisin13lowincomeandmiddleincomecountries
AT ravinettoraffaella pharmaceuticalqualityassuranceoflocalprivatedistributorsasecondaryanalysisin13lowincomeandmiddleincomecountries